Skip to main content
Premium Trial:

Request an Annual Quote

Gawande Tapped for USAID Role

President Joe Biden has nominated Atul Gawande to lead global health development at the US Agency for International Development, according to Stat News.

Gawande, a surgeon, Harvard University professor, and writer for the New Yorker, previously served as chief executive of Haven, a venture between Amazon, Berkshire Hathaway, and JPMorgan Chase to improve healthcare while bringing down costs, before resigning in 2020. Stat News adds that, during the pandemic, Gawande co-founded CIC Health, which aims to help with COVID-19 testing and vaccination efforts. He also served on Biden's COVID-19 advisory panel during the transition and, as Reuters notes, was senior advisor in the Department of Health and Human Services during the Clinton Administration.

Reuters reports that Gawande's role at USAID — if he is confirmed by the Senate — will involve addressing child and maternal deaths, the HIV/AIDS epidemic, and infectious diseases like COVID-19. "With more COVID deaths worldwide in the first half of 2021 than in all of 2020, I’m grateful for the chance to help end this crisis and to re-strengthen public health systems worldwide," Gawande says in a tweet.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.